These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31583784)

  • 1. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis.
    Kapoor M; Foiani M; Heslegrave A; Zetterberg H; Lunn MP; Malaspina A; Gillmore JD; Rossor AM; Reilly MM
    J Peripher Nerv Syst; 2019 Dec; 24(4):314-319. PubMed ID: 31583784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy.
    Maia LF; Maceski A; Conceição I; Obici L; Magalhães R; Cortese A; Leppert D; Merlini G; Kuhle J; Saraiva MJ
    Amyloid; 2020 Jun; 27(2):97-102. PubMed ID: 31906707
    [No Abstract]   [Full Text] [Related]  

  • 3. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
    Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
    Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
    Galosi E; Costanzo R; Forcina F; Morino S; Antonini G; Salvetti M; Lauletta A; Luigetti M; Romano A; Primiano G; Guglielmino V; Fionda L; Garibaldi M; Esposito N; Falco P; di Pietro G; Truini A; Leonardi L
    Neurol Sci; 2024 Oct; 45(10):5023-5032. PubMed ID: 38700599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
    Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
    Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin-related amyloidosis-A Swiss reference center experience.
    Loser V; Benkert P; Vicino A; Lim Dubois Ferriere P; Kuntzer T; Pasquier J; Maceski A; Kuhle J; Theaudin M
    J Peripher Nerv Syst; 2023 Mar; 28(1):86-97. PubMed ID: 36471582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
    Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
    Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological affection and serum neurofilament light chain in wild type transthyretin amyloidosis.
    Pernice HF; Knorz AL; Wetzel PJ; Herrmann C; Muratovic H; Rieber F; Asaad E; Fiß G; Barzen G; Blüthner E; Knebel F; Spethmann S; Messroghli D; Heidecker B; Brand A; Wetz C; Tschöpe C; Hahn K
    Sci Rep; 2024 May; 14(1):10111. PubMed ID: 38698025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).
    Chan GG; Koch CM; Connors LH
    J Proteome Res; 2017 Nov; 16(11):4104-4112. PubMed ID: 28922609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis.
    Chan GG; Koch CM; Connors LH
    J Proteome Res; 2017 Apr; 16(4):1659-1668. PubMed ID: 28196416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review.
    Cruz MW
    Clin Auton Res; 2019 Sep; 29(Suppl 1):19-24. PubMed ID: 31407119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis.
    Lin X; Yarlas A; Vera-Llonch M; Baranwal N; Biber J; Brown D; Vogt B; Karam C
    BMC Neurol; 2021 Feb; 21(1):70. PubMed ID: 33579211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog.
    Perino J; Patterson M; Momen M; Borisova M; Heslegrave A; Zetterberg H; Gruel J; Binversie E; Baker L; Svaren J; Sample SJ
    Neurosci Lett; 2021 Jan; 744():135593. PubMed ID: 33359734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis.
    Wixner J; Törnblom H; Karling P; Anan I; Lindberg G
    Neurogastroenterol Motil; 2018 Sep; 30(9):e13354. PubMed ID: 29655299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
    Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
    Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Neurofilament Light Chain Is Associated with Poor Functional Outcome and Mortality Rate After Spontaneous Subarachnoid Hemorrhage.
    Hviid CVB; Lauridsen SV; Gyldenholm T; Sunde N; Parkner T; Hvas AM
    Transl Stroke Res; 2020 Aug; 11(4):671-677. PubMed ID: 31808039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament Light Chains in Systemic Amyloidosis: A Systematic Review.
    Berends M; Nienhuis HLA; Adams D; Karam C; Luigetti M; Polydefkis M; Reilly MM; Sekijima Y; Hazenberg BPC
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.